EGFR and non-small cell lung carcinoma: MEK and PI3K inhibitors can inhibit cell proliferation in NSCLC; however, for apoptosis activation, both signaling pathways must be simultaneously inhibited [40, 41], a situation that is directly related to the frequently observed EGFR-TKI resistance in this tumor.